中国现代医生2024，Vol.62Issue(1)：39-42,4.DOI:10.3969/j.issn.1673-9701.2024.01.010
免疫治疗联合放化疗对晚期食管癌疗效及安全性的回顾性研究
A retrospective study:The efficacy and safety of immunotherapy combined with radiochemotherapy for advanced esophageal cancer
摘要
Abstract
Objective To contrast the efficacy and safety of immune checkpoint inhibitor(ICI)combined with radiochemotherapy and concomitant radiochemotherapy in the treatment of advanced esophageal cancer.Methods The clinical data of 67 patients with advanced esophageal cancer who were treated in the Second Hospital of Anhui Medical University from January 2019 to January 2023 were retrospectively analyzed.Patients were divided into combination group(n=35)and radiochemotherapy group(n=32)according to different treatment plans.Progress free survival(PFS),objective remission rate(ORR),disease control rate(DCR)and adverse reactions were compared between two groups.Results The median PFS in combination group was significantly longer than that in radiochemotherapy group(12.6 months vs.6.3 months,χ2=16.288,P<0.001).ORR in combination group was significantly higher than that in radiochemotherapy group(54.3%vs.21.9%,P=0.011).DCR in combination group was significantly higher than that in radiochemotherapy group(77.1%vs.53.1%,P=0.045).The incidence of treatment-related adverse reactions and radiochemotherapy-related adverse reactions in combination group were significantly lower than those in radiochemotherapy group(P<0.05).There were 11 cases of immune-related adverse reactions in combination group,all of which were grade 1-2 adverse reactions.Conclusion ICI combined with radiochemotherapy can improve the curative effect of patients with advanced esophageal cancer,and the adverse reactions are acceptable.关键词
食管癌/免疫检查点抑制剂/不良反应/疗效Key words
Esophageal cancer/Immune checkpoint inhibitor/Adverse reaction/Therapeutic effect分类
医药卫生引用本文复制引用
李炳冰,张明军..免疫治疗联合放化疗对晚期食管癌疗效及安全性的回顾性研究[J].中国现代医生,2024,62(1):39-42,4.基金项目
安徽省自然科学基金项目(S201902b05020149) （S201902b05020149）
